Psylink operates a dual R&D strategy combining a sustainable biotechnology platform with natural product discovery to develop novel mental health therapies. The company engineers yeast cells as biosynthetic "mini-factories" to produce plant- and fungi-derived compounds at scale, offering an environmentally friendly alternative to chemical synthesis and extraction. Its discovery work focuses on psilocybin and related fungal metabolites to uncover new treatment candidates for conditions such as depression and PTSD. Psylink targets patients who do not respond to conventional therapies; the article notes an estimated 30–40% of individuals experience little to no benefit from standard antidepressants. The funding will support advancement of the proprietary platform, the screening and evaluation of molecular candidates, and acceleration of preclinical validation.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2025